VBIO SEC Filings: 8-K, 10-Q, S-3 & 424B – Valion Bio

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 14, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 14, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mar 30, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 14, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 14, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 15, 2025

News

TYPE

HEADLINE

FILED AT

8-K

NEWValion Bio Enters into Fifth 3i Side Letter, Issuing Series B Preferred Shares and Warrants for $700,000

Nov 9, 2026

8-K

Valion Bio, Inc. Announces Resignation of President, COO, and CFO Lisa Wolf

Nov 5, 2026

8-K

Valion Bio Advances Entolimod into U.S. Government-Funded Therapeutic Efficacy Study for GI-ARS

Nov 2, 2026

8-K

Valion Bio Announces Positive Safety Results from U.S. Government-Funded Entolimod Study

Oct 29, 2026

8-K

Valion Bio Announces Series B and Series C Closings Totaling Over $4.7 Million

Oct 27, 2026

8-K

Unsolicited Acquisition Interest Prompts Evaluation of Strategic Options for Wholly Owned Biologics CDMO Subsidiary

Oct 26, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B3

SHARE RESALE REGISTRATION | Shares: 3,954,381

Oct 20, 2026

424B3

SHARE RESALE REGISTRATION | Shares: 956,222

Apr 15, 2026

424B3

SHARE RESALE REGISTRATION | Shares: 13,659,638

Jan 20, 2026

424B3

SHARE RESALE REGISTRATION | Shares: 36,135,295

Jan 20, 2026

424B3

UPDATED | SHARE RESALE REGISTRATION | Shares amount: 1,580,437 | Warrants amount: 195,793 | Conversion price: $1.29

Dec 12, 2025

424B3

UPDATED | SHARE RESALE REGISTRATION | Shares amount: 1,592,135 | Warrants amount: 188,842 | Conversion price: $1.29

Dec 12, 2025

Registrations

TYPE

HEADLINE

FILED AT

Proxies

TYPE

HEADLINE

FILED AT

DEF 14A

Form DEF 14A - Other definitive proxy statements

Oct 16, 2026

PRE 14A

Form PRE 14A - Other preliminary proxy statements

Oct 5, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Jul 17, 2026

PRE 14A

Form PRE 14A - Other preliminary proxy statements

Jul 7, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 30, 2026

PRE 14A

Form PRE 14A - Other preliminary proxy statements

Apr 20, 2026

Ownerships

TYPE

HEADLINE

FILED AT

S-3

Form S-3 - Registration statement under Securities Act of 1933

Oct 16, 2026

S-3

Form S-3 - Registration statement under Securities Act of 1933

Oct 7, 2026

Zikria Dean (Reporting)

Sep 24, 2026

Wolf Lisa G (Reporting)

Sep 24, 2026

Malbin Jared David (Reporting)

Sep 17, 2026

Jensen Thomas (Reporting)

Sep 17, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Oct 21, 2026

EFFECT

Form EFFECT - Notice of Effectiveness

Oct 21, 2026

EFFECT

Form EFFECT - Notice of Effectiveness

Aug 13, 2026

EFFECT

Form EFFECT - Notice of Effectiveness

Apr 16, 2026

CORRESP

Form CORRESP - Correspondence

Apr 13, 2026

LETTER

Form UPLOAD - SEC-generated letter

Apr 9, 2026

Valion Bio, Inc. VBIO · SEC Filings